Protalix Biotherapeutics Company Insiders

PLX Stock  USD 1.10  0.15  12.00%   
Protalix Biotherapeutics employs about 208 people. The company is managed by 4 executives with a total tenure of roughly 11 years, averaging almost 2.0 years of service per executive, having 52.0 employees per reported executive. Break down of Protalix Biotherapeutics' management performance can provide insight into the company performance.
Dror Bashan  CEO
President CEO
Yaron Naos  President
Senior Vice President - Operations
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Protalix Biotherapeutics Management Team Effectiveness

The company has Return on Asset of 0.0933 % which means that on every $100 spent on assets, it made $0.0933 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.725 %, implying that it generated $0.725 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.28 in 2024, whereas Return On Equity is likely to drop 0.24 in 2024. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.10 in 2024, whereas Total Assets are likely to drop slightly above 51 M in 2024.
Common Stock Shares Outstanding is likely to rise to about 86.5 M in 2024, whereas Net Loss is likely to drop (14.1 M) in 2024.

Protalix Biotherapeutics Workforce Comparison

Protalix Biotherapeutics is regarded fifth in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 2,240. Protalix Biotherapeutics holds roughly 208 in number of employees claiming about 9% of equities under Health Care industry.

Protalix Biotherapeutics Profit Margins

The company has Net Profit Margin of 0.13 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of (0.54) %, which entails that for every $100 of revenue, it lost $0.54.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.680.6491
Sufficiently Up
Slightly volatile

Protalix Biotherapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protalix Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protalix Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Protalix Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Protalix Biotherapeutics Notable Stakeholders

A Protalix Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Protalix Biotherapeutics often face trade-offs trying to please all of them. Protalix Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Protalix Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dror BashanPresident CEOProfile
Yaron NaosSenior Vice President - OperationsProfile
Eyal MBACFO, VPProfile
Yael FellousVice ResourcesProfile

About Protalix Biotherapeutics Management Performance

The success or failure of an entity such as Protalix Biotherapeutics often depends on how effective the management is. Protalix Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Protalix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Protalix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.1  0.10 
Return On Capital Employed 0.27  0.28 
Return On Assets 0.1  0.10 
Return On Equity 0.25  0.24 
The data published in Protalix Biotherapeutics' official financial statements usually reflect Protalix Biotherapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Protalix Biotherapeutics. For example, before you start analyzing numbers published by Protalix accountants, it's critical to develop an understanding of what Protalix Biotherapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Protalix Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Protalix Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Please utilize our Beneish M Score to check the likelihood of Protalix Biotherapeutics' management manipulating its earnings.

Protalix Biotherapeutics Workforce Analysis

Traditionally, organizations such as Protalix Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Protalix Biotherapeutics within its industry.

Protalix Biotherapeutics Manpower Efficiency

Return on Protalix Biotherapeutics Manpower

Revenue Per Employee314.9K
Revenue Per Executive16.4M
Net Income Per Employee40K
Net Income Per Executive2.1M
Working Capital Per Employee117.3K
Working Capital Per Executive6.1M
When determining whether Protalix Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protalix Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protalix Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protalix Biotherapeutics Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Protalix Stock analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.39)
Earnings Share
0.09
Revenue Per Share
0.97
Quarterly Revenue Growth
0.217
Return On Assets
0.0933
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.